NATCO Pharma shares decline over 33% in last five trading sessions, here’s why

On Thursday, the drug manufacturer cracked the lower circuit at ₹975.05 per equity price, down 19.99% on the NSE. During the last trading session, the stock had hit a lower circuit of ₹973.35, before closing at ₹973.4 on the Bombay Stock Exchange (BSE).

Natco Pharma’s disappointing Q3 result

The pharmaceutical reported a 37.75% year-on-year decline in its consolidated net profit to ₹132.4 crore in the third quarter of the 2024-25 financial year (Q3FY25) amid a fall in its formulations exports.

NATCO’s revenue from formulation exports stood at ₹285.8 crore, falling 52.81% year-on-year (YoY) from ₹605.6 crore in Q3 FY24. It dropped 76.41% sequentially from ₹1,211.3 crore in the previous quarter.

Its revenue from operations was at ₹474.8 crore in the December quarter of FY25, falling 37.41% YoY from ₹758.6 crore in the same period a year ago.

Past stock performance

At 12:11 pm, NATCO is trading at ₹884.1 per share price, down 9.33% on the NSE.

The stock fell 33.35% over the last five days and 25.05% in the last month. It was down 36.43% over the last six months and 36.2% on a year-to-date basis.

NATCO Pharma’s market capitalisation eroded about ₹6,000 crore to ₹15,728.53 crore since it declared its Q3 results.

The company hit its 52-week low of ₹848.05 on the NSE, exactly a year ago on February 14, 2024. It reached its 52-week high of ₹1,639 on September 12, 2024.